Koyfin Home > Directory > Health Care > Amicus Therapeutics > Gross Margin

Amicus Therapeutics Gross Margin Chart (FOLD)

Amicus Therapeutics annual/quarterly Gross Margin from 2007 to 2018. Gross margin is a company's total sales revenue minus its cost of goods sold (COGS), divided by total sales revenue, expressed as a percentage. The higher the percentage, the more the company retains on each dollar of sales, to service its other costs and debt obligations.
  • Amicus Therapeutics Gross Margin for the quarter ending December 12, 2018 was $87m a 2.72% increase of 2m year over year
  • Amicus Therapeutics Gross Margin for the last 12 months ending December 12, 2018 was $84m a 0.65% increase of 1m year over year
  • Amicus Therapeutics Annual Gross Margin for 2018 was $84m a 1.31% increase of 1m from 2017
  • Amicus Therapeutics Annual Gross Margin for 2017 was $83m a -0.10% decrease of 0m from 2016
  • Amicus Therapeutics Annual Gross Margin for 2016 was $83m a -20.19% decrease of -17m from 2015
Other Margins & Efficiency Metrics:
  • Amicus Therapeutics EBITDA Margin for the quarter ending December 12, 2018 was $-208m a 36.06% decrease of -75m year over year
  • Amicus Therapeutics Return on Capital % for the quarter ending September 09, 2018 was -53.00 a 52.45% decrease of -27.80 year over year
  • Amicus Therapeutics Return on Equity % for the quarter ending September 09, 2018 was -130.88 a 44.52% decrease of -58.28 year over year
View Chart On Koyfin

Quarterly FOLD Gross Margin Data

12/2018$87m
09/2018$79m
06/2018$85m
03/2018$84m
12/2017$82m
09/2017$84m
06/2017$85m
03/2017$81m
12/2016$83m
09/2016$84m

Annual FOLD Gross Margin Data

2018$84m
2017$83m
2016$83m
2014$100m
2012$-11m
2011$-13m
2009$68m
2008$21m